Overview

A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
A Pharmacokinetic study of once daily Efavirenz 400 mg versus 600 mg in Thai HIV-1 infected subjects.
Phase:
Phase 2
Details
Lead Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborator:
Ministry of Education, Thailand
Treatments:
Efavirenz